| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 310 | 510 | 2,480 | 3,700 | 36,550 |
| Sales Growth | -39.22% | -79.44% | -32.97% | -89.88% | +21.15% |
| Net Income | 380 | 10,280 | -88,030 | -155,020 | -150,720 |
| Net Income Growth | -96.30% | +111.68% | +43.21% | -2.85% | -78.05% |
Liminal Biosciences Inc (LMNL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Liminal BioSciences Inc. is a biotechnology company. It engages in discovering, developing and commercializing novel small molecule compounds for respiratory, liver and renal diseases. The company's product pipeline consists of PBI-4050, which are in clinical stage. Liminal BioSciences Inc., formerly known as Prometic Life Sciences Inc., is based in Laval, Canada.
Fiscal Year End Date: 12/31